Opioid Support and Risk Reduction Online Platform

阿片类药物支持和降低风险在线平台

• 批准号: 10013077
• 负责人: Renee Garett
• 金额: $ 23.9万
• 依托单位: ELEVATEU
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10013077
• 关键词: Address; Affect; Anxiety; Area; Artificial Intelligence; Behavioral; Businesses; Chronic; Clinical; Clinical Data; Clinical Psychology; Cognitive Therapy; Communities; Computer software; Counseling; Data Science; Development; Education; Educational Intervention; Effectiveness; Environment; Epidemic; Facebook; Feedback; Fentanyl; Funding; Future; Goals; Health; Health Benefit; Health behavior; Health behavior change; Health system; Helping to End Addiction Long-term; Heroin; Heroin Users; Insurance Carriers; Intellectual Property; Intervention; Lawyers; Lead; Learning; Legal patent; Licensing; Link; Media Intervention; Medical; Mental Health; Nonpharmacologic Therapy; Opioid; Outcome; Overdose; Participant; Patients; Pharmaceutical Preparations; Phase; Physicians; Pilot Projects; Population; Prevention; Public Health; Randomized Controlled Trials; Recording of previous events; Research; Risk; Risk Factors; Risk Reduction; Running; Silicon; Small Business Innovation Research Grant; Social support; Surgeon; System; Technology; Testing; Time; United States; addiction; base; behavior change; chronic pain; chronic pain patient; clinically relevant; commercialization; community intervention; cost; design; digital health; evidence base; experience; feasibility testing; heroin use; high risk; improved; innovation; misuse of prescription only drugs; non-cancer pain; novel; online community; opioid abuse; opioid epidemic; opioid misuse; opioid overdose; opioid therapy; opioid user; pain patient; patients who use opioids; peer; predictive modeling; prescription opioid; prevent; programs; satisfaction; social media; social stigma; substance use; success

Project Summary This proposal seeks to determine the feasibility, acceptability, and preliminary efficacy of developing an online support and risk reduction platform to prevent opioid misuse and abuse. This is an urgent area of research; opioid misuse/abuse has reached epidemic proportions in recent years. It is linked to causing the largest drug epidemic in the history of the United States and has become the top priority of the US Surgeon General. Because the opioid crisis (including heroin use) is believed to have largely originated from chronic pain patients' opioid prescriptions, this application will initially focus on the needs of chronic pain patients on opioids who are high risk for addiction and overdose. Later versions of the technology will expand to the broader population of people affected by the opioid crisis, including heroin users. Although low cost, novel interventions are needed to reduce opioid misuse and abuse, before they lead to addiction and fatal overdose, only 6 behavioral (non-pharmacological) randomized controlled trials have been successfully conducted in this area to date (with our group having conducted one of them), creating a tremendous need for solutions to the opioid crisis. Building off extensive preliminary research that our team conducted, including piloting technology-based behavior change interventions among chronic pain patients, and developing artificial intelligence (AI)-based prediction models of opioid outcomes, we propose to design and test the feasibility, acceptability, and preliminary efficacy of an online peer social support and clinical counseling community to reduce opioid misuse/abuse among chronic pain sufferers. This is a highly innovative product with scalable commercialization potential and impact as 1) no software platform exists that has been shown to reduce opioid misuse/abuse risk factors, 2) it is evidenced- based, supported by more than a decade of scientific research conducted by our team, and 3) is highly accessible, helping to address the time, cost, and stigma that are constant barriers to opioid prevention and treatment. Our team includes the former CFO of Epic Systems (and two-time successful entrepreneur), the Associate Chief Medical Information Officer for Cedars-Sinai, a patent attorney at a large Silicon Valley intellectual property firm specializing in digital health portfolios, as well as clinical, data science/statistical, and research experts who conducted more than a decade of formative research leading up to this application. Funding for this Phase 1 SBIR is needed before scaling development and testing more widely among potential health system and insurer customers.

项目概要 该提案旨在确定开发一个 在线支持和风险降低平台，防止阿片类药物误用和滥用。这是一个紧迫的领域 研究;近年来，阿片类药物误用/滥用已达到流行病的程度。它与导致 美国历史上最大规模的毒品流行，已成为美国外科医生的首要任务 一般的。因为阿片类药物危机（包括海洛因使用）被认为很大程度上源于慢性 疼痛患者的阿片类药物处方，该应用程序最初将关注慢性疼痛患者的需求 阿片类药物成瘾和服用过量的风险很高。该技术的后续版本将扩展到 受阿片类药物危机影响的更广泛人群，包括海洛因使用者。 尽管成本较低，但在导致阿片类药物滥用和滥用之前仍需要采取新的干预措施 成瘾和致命的过量用药，只有 6 项行为（非药理学）随机对照试验得到了证实 迄今为止在这一领域已成功开展（我们的小组已开展其中一项），创造了 迫切需要解决阿片类药物危机。我们的团队以广泛的初步研究为基础 进行的，包括在慢性疼痛患者中试点基于技术的行为改变干预措施， 并开发基于人工智能（AI）的阿片类药物结果预测模型，我们建议设计 测试在线同伴社会支持和临床的可行性、可接受性和初步效果 向社区提供咨询，以减少慢性疼痛患者中阿片类药物的误用/滥用。 这是一种高度创新的产品，具有可扩展的商业化潜力和影响力：1) 否 存在的软件平台已被证明可以减少阿片类药物滥用/滥用的风险因素，2）有证据表明 - 基于我们团队十多年的科学研究的支持，并且 3) 高度 易于获取，有助于解决阿片类药物预防和治疗的持续障碍的时间、成本和耻辱问题 治疗。 我们的团队包括 Epic Systems 的前首席财务官（以及两次成功的企业家）、助理 Cedars-Sinai 首席医疗信息官、硅谷一家大型知识分子的专利律师 专注于数字健康投资组合以及临床、数据科学/统计和研究的房地产公司 专家们进行了十多年的形成性研究，最终促成了这一应用。资助 在潜在健康人群中更广泛地扩展开发和测试之前，需要进行第一阶段 SBIR 系统和保险公司客户。